A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease
patients will be taking part in this study
Drug: Etrolizumab 210 mg Drug: Etrolizumab 105 mg Drug: Placebo
GI Research Institute, Suite 770-1190 Hornby Street, Vancouver, British Columbia, Canada
This is a multicenter, Phase III, double-blind, placebo-controlled study evaluating the safety and efficacy of etrolizumab during induction and maintenance treatment of moderate to severely active Crohn's disease (CD) in patients who are anti-tumor necrosis factor (TNF) naive (TNF-naive) and in patients who are refractory or intolerant of tumor necrosis factor inhibitors.
Full Trial Details